Orexo, GAIA to develop digital therapeutic for opioid use disorder

Via a deal with German digital therapeutics company GAIA, Orexo will develop a psychosocial support product intended to enhance the use of Zubsolv buprenorphine/naloxone, its treatment for opioid use disorder (OUD).

For its first digital therapeutic, Orexo AB (SSE:ORX) will collaborate with GAIA AG (Hamburg, Germany) to develop a web-based product that provides simulated interactions with a virtual counselor available around the clock to patients with OUD, Orexo President and CEO Nikolaj Sørensen told BioCentury...